Optimization of Versatile Oxindoles as Selective PI3Kδ Inhibitors.

ACS Med Chem Lett

Discovery Chemistry, Computational and Structural Chemistry, In Vitro Pharmacology, Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Merck & Co., Inc., Boston, Massachusetts 02115, United States.

Published: December 2020

The 3,3-disubstituted oxindole moiety is a versatile and rigid three-dimensionally shaped scaffold. When engineered with a purine hinge-binding core, exceptionally selective PI3Kδ kinase inhibitors were discovered by exploiting small differences in isoform selectivity pockets. Crystal structures of early lead bound to PI3Kδ and PI3Kα helped rationalize the high selectivity observed with . By attenuating the lypophilicity and metabolic liabilities of an oxindole moiety, we improved the preclinical species PK and solubility and reduced adenosine uptake activity. The excellent potency and kinome selectivity of 7-azaoxindole and spirooxindole , together with a low plasma clearance and good half-life in rat and dog, supported a low once-daily predicted human dose.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7734802PMC
http://dx.doi.org/10.1021/acsmedchemlett.0c00441DOI Listing

Publication Analysis

Top Keywords

selective pi3kδ
8
oxindole moiety
8
optimization versatile
4
versatile oxindoles
4
oxindoles selective
4
pi3kδ inhibitors
4
inhibitors 33-disubstituted
4
33-disubstituted oxindole
4
moiety versatile
4
versatile rigid
4

Similar Publications

Objective And Significance: Transforming growth factor-beta (TGF-β) plays a pivotal role in breast development by modulating tissue composition during the developmental phase. The TGFβ type II receptor (TGFβ RII) is implicated in breast cancer and represents a valuable therapeutic target. Due to the off-target side effects of many existing TGFβI/TGFβ RII inhibitors, a more targeted approach to drug discovery is necessary.

View Article and Find Full Text PDF

Background: Solid organ transplantation (SOT) is vital for end-stage organ failure but faces challenges like organ shortage and rejection. Artificial intelligence (AI) offers potential to improve outcomes through better matching, success prediction, and automation. However, the evolution of AI in SOT research remains underexplored.

View Article and Find Full Text PDF

A systematic review of measurement tools and senior engagement in urban nature: Health benefits and behavioral patterns analysis.

Health Place

January 2025

Department of Forest Resources Management, Faculty of Forestry, University of British Columbia, Vancouver, V6T 1Z4, Canada. Electronic address:

The engagement of senior citizens with urban nature has been shown to provide multiple health benefits and mitigate health issues associated with demographic aging. This review utilized the PRISMA methodology to systematically analyze the relationship between monitoring tools, seniors' behaviors in urban nature, and influencing factors. The main findings are as follows: (1) 4 main types, including self-reports, on-site observations, sensors, and third-party data, and 24 sub-types of measurement tools: ranging from questionnaires to crowdsourced imagery services.

View Article and Find Full Text PDF

EGFR inhibitors are a class of targeted therapies utilized in the management of certain tumor kinds such as NSCLC and breast cancer. Series of 1,2,3-triazole-Schiff's base hybrids were designed, synthesized, and estimated for their antitumor effect toward breast cancer cells, MCF-7 and MDA-MB-231. The safety and selectivity of the new compounds were tested using normal cell (WI-38).

View Article and Find Full Text PDF

Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes : A Systematic Review of Randomized Controlled Trials.

Ann Intern Med

January 2025

Centre of Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital; Division of Experimental Medicine, McGill University; Department of Epidemiology, Biostatistics and Occupational Health, McGill University; Department of Medicine, McGill University; and Division of Cardiology, Jewish General Hospital/McGill University, Montreal, Quebec, Canada (M.J.E.).

Background: Recent randomized controlled trials (RCTs) have investigated glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual or triple co-agonists for weight loss among adults with overweight or obesity and without diabetes.

Purpose: To assess the efficacy and safety of GLP-1 RAs and co-agonists for the treatment of obesity among adults without diabetes.

Data Sources: MEDLINE, Embase, and Cochrane CENTRAL from inception to 4 October 2024.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!